Escient Pharmaceuticals: PACIFIC Study - EP547 in Subjects With Cholestatic Pruritus

2021 Talyor, K, et al. FIRST-IN-HUMAN STUDY OF EP547, A POTENT AND HIGHLY SELECTIVE MRGPRX4 INVERSE AGONIST IN DEVELOPMENT FOR TREATMENT OF CHOLESTATIC PRURITUS. HEPATOLOGY, VOLUME 74, NUMBER 1 (SUPPL), AASLD Abstracts. Please find Abstract #1272. Text available without subscription at doi/epdf/10.1002/hep.32188. Notes: Results of a phase 1 safety study of EP547.